Eloxx Pharmaceuticals (ELOX) Issues Quarterly Earnings Results

Eloxx Pharmaceuticals (OTCMKTS:ELOX) announced its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03, MarketWatch Earnings reports.

OTCMKTS ELOX opened at $17.04 on Friday. Eloxx Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $24.60.

Separately, Zacks Investment Research raised shares of Eloxx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $25.25.

Several hedge funds and other institutional investors have recently bought and sold shares of ELOX. Strs Ohio bought a new stake in shares of Eloxx Pharmaceuticals in the second quarter valued at approximately $107,000. Tower Research Capital LLC TRC bought a new stake in shares of Eloxx Pharmaceuticals in the second quarter valued at approximately $146,000. Renaissance Technologies LLC bought a new stake in shares of Eloxx Pharmaceuticals in the second quarter valued at approximately $171,000. Rhumbline Advisers bought a new stake in shares of Eloxx Pharmaceuticals in the second quarter valued at approximately $337,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Eloxx Pharmaceuticals in the second quarter valued at approximately $1,038,000.

COPYRIGHT VIOLATION WARNING: “Eloxx Pharmaceuticals (ELOX) Issues Quarterly Earnings Results” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thelincolnianonline.com/2018/11/10/eloxx-pharmaceuticals-elox-issues-quarterly-earnings-results.html.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

See Also: Hedge Funds – Risk or Reward?

Earnings History for Eloxx Pharmaceuticals (OTCMKTS:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply